86P Post-operative radiotherapy (PORT) vs non-PORT in non-small cell lung cancer patients: A systematic review and meta-analysis

Abstract

Prospective data of thirty-three consecutive patients with inoperable stage III NSCLC completed CRT with sequential Durvalumab (77%, 22 patients) or concurrent and sequential Nivolumab (33%, 11 patients) were analyzed. Different cut offs for PTV were evaluated for association with progression-free (PFS) survival. Results: All patients were treated with conventionally fractionated TRT; 93% to a total dose of at least 60 Gy (range: 60-63.6Gy). 97% of patients received two cycles of concurrent platinum-based chemotherapy. Median follow-up for the entire cohort was 19.9 (range: 6.0-42.4) months; median overall survival (OS) was not reached. Median Progression-free survival (PFS) was 22.8 (95% CI: 10.7-34.8) months. Patients with PTV ≥ 900ccm had a significantly shorter PFS (6.9 vs 22.8 months, p = 0.020) and extracranial metastasis free survival (eMFS) (8.1 months vs not reached, p = 0.026). Furthermore, patients with PTV ≥ 900ccm and stage IIIC disease (TNM 8 th Ed.) achieved a dismal median PFS of only 3.5 months (vs. 26.3 months p = 0.022). Conclusions: PTV has a significant impact on the PFS and eMFS after CRT combined with concurrent and/or sequential CPI in inoperable stage III NSCLC. Patients with PTV ≥ 900ccm had a significantly shorter PFS and eMFS.